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Abstract                      
Introduction: Fragile X syndrome (FXS) is one of the most prevalent genetic causes of 
developmental disability, representing the most frequent form of inherited severe cognitive 
deficit. The present study was undertaken to investigate FXS and its prevalence in moderate 
mentally retarded people in patients. 
Materials and methods: Nineteen people with moderate mental retardation (MR) who were 
clinically suspicious to have FXS were screened for FXS by using cytogenetic and molecular 
methods. Blood samples were collected and cultured in specific culture media. G-Banding 
method was used for karyotyping. To ensure correct results of cytogenetic testing, four 
suspected case of FXS were tested by PCR. Results were analyzed using logistic regression 
analysis. 
Results: Four patients (4%) were found to express fragile X site at q27.3. The results showed 
that the relationship of FXS with familial, economic status was not significant, but the 
relationship of FXS with MR and family history was significant. 
Conclusion: The frequency of FXS positive cases found in this study is similar to other reports 
of FXS in preselected patients. 
Keywords: MR, FXS, FMR1, Cytogenetic
Introduction 
Mental retardation (MR) means delay in 
mental development; it means an 
impairment of the intellectual processes of 
the mind, making it difficult for the person 
to cope with environment in which they 
find themselves. FXS (FXS) is one of the 
most prevalent genetic causes of MR, 
representing the most frequent form of 
inherited severe cognitive deficit, second 
only to Down syndrome as a genetic cause 
of MR. It is estimated that the FXS affects 
approximately 1 in 2,500 individuals (1-
4).The syndrome is inherited as an X-linked 
dominant trait with reduced penetrance 
80% in males and 30% in females (5). 
According to studies conducted in Iran the 
frequency of FXS have been reported to be 
63% (6). The syndrome is mainly 
characterized by a variable degree of MR, 
typical long and narrow facial appearance 
with large ears, prominent fontanels and 
large testis (7). FXS can be cytogenetically 
diagnosed by the expression of 
chromosome X-fragile site at band Xq27.3 
(8). The unique mutation that results in FXS 
consists of expansion of the CGG 
trinucleotide repeats (>200) in the 3' 
untranslated region of the FMR-I gene at 
Xq27.3 as well as hypermethylation of the 
repeat and its flanking region resulting in 
absence of the FMRI protein (9). FMR1 is 
a highly conserved gene that consists of 17 
exons and spans ∼38 kb (10-11). Within the 
4.4 kb of FMR1 transcript, a CGG 
trinucleotide repeat is located at the 5′-
untranslated region (5′-UTR). Among 
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normal individuals, this CGG repeat is 
highly polymorphic in length and content, 
often punctuated by AGG interruptions (12-
16). The normal repeat size ranges from 7 
to ∼60, with 30 repeats found on the most 
common allele. In most affected 
individuals, a CGG repeat are massively 
expanded over 230 repeats (full mutation) 
and becomes abnormally hypermethylated, 
which results in the silence of the FMR1 
gene. Alleles with between 60 and 230 
CGG repeats are called permutation. They 
are generally unmethylated with normal 
transcript and protein level, but are 
extremely unstable during transmission to 
next generation (17). Expansion of 
premutation into full mutation can only 
occur by maternal transmission and 
depends on the length of the maternal pre 
mutation. Due to X-linkage, affected males 
have more severe phenotypes than affected 
females, whose phenotype is modulated by 
the activation ratio of the normal X 
chromosome. Identification of other 
mutations of the FMR1 gene, such as 
deletions and point mutation among 
patients with usual phenotype but without 
fragile site expression, firmly established 
that the FMR1 gene is the only gene 
involved in the pathogenesis of FXS (18). 
Thus, the absence of the FMR1 gene 
product, fragile X MR protein (FMRP), is 
the typical cause of FXS (18). 
Laboratory diagnosis of FXS by various 
methods, such as Southern blot, PCR and 
Karyotype is detected and which in this 
study two methods, karyotype and PCR 
were used. Power to detect a suspected 
diagnosis of FXS karyotype is 99 percent 
for men and 95 percent for women have 
been reported (16-18). Due to high PCR 
accuracy for diagnosis of FXS, in 7 patients 
who showed signs of phenotypic Better, 
PCR analysis was used to identify these 
individuals. Since there is no statistical 
analysis concerning this field in east of Iran 
, thus collected data on incidence of the 
disease in the district, has a valuable 
importance in management of the disease, 
genetic consultation, and designing future 
plans for patients. 
Materials and methods 
In this descriptive study, 90 mentally 
retarded (MR) males were selected from 
MR centers of Kermansh, Sanandaj and 
Abhar cities. 
Cytogenetic method: 5ml of peripheral 
heparinized blood were taken from patients 
provided and then immediately transferred 
to Sanandaj Research Laboratory of 
Genetics and cell culture according to 
standard procedures was performed on the 
FXS Karyotype (11). In this study, the 
RPMI 1640 medium containing 25% fetal 
bovine serum (FBS) , antibiotics as 
Penicillin (300 mg/ml) and thymidine 
(300µg/ml) were used (products of GIBCO 
and Sigma). Medium under the hood and 
near the flame, were prepared. For 
cultivation 5 ml of cell culture medium to 
each tube, 0.1 ml Phytohemaglutinin (PHA) 
and 0.5 ml peripheral blood were added and 
incubated for 72 h with 5% CO2 at 37 °C 
and incubated respectively. Tubes 
containing medium every day were gently 
shaken to the same medium. After this to 
each tube containing medium, 0.1 ml of 
colcemid was added and after half an hour 
harvesting steps was done. Tubes were 
placed for 15 minutes in the serologic bath. 
After centrifugation at 1200 rpm for 10 
min, cells isolated from the culture medium 
and were impressed with the hypotonic 
solution (KCl0.75 M). After centrifugation 
the cells were exposed to the fixative 
solution (acetic acid and methanol at a ratio 
of 1 to 3) placed, and they were centrifuged 
again. After several washing steps with 
fixative solution, a clear suspension of 
lymphocytes obtained and drop shot 
technique was used with sterile Pasteur 
pipette several slides were prepared from 
each sample (12-13). With the G-banding 
method, metaphase spreads were prepared 
on the slides (14). First, metaphase spreads 
were exposed trypsin for 15 seconds then 
placed in Giemsa solution. After 10 
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distilled water. Pictures taken from slides of 
each patient and using software 
karyotyping were analyzed and descriptive 
statistics were diagnosed. 
Molecular methods: Genomic DNA from 
peripheral blood lymphocytes by standard 
method of salting was extracted. Primers 
for amplification of FMR-1 gene designed 
and produced (15). Amplification products 
were resolved by %8 Polyacrylamide gel 
electrophoresis (PAGE). The gels were 
silver-stained according to Bassam’s 
protocol (16). Molecular analysis (PCR) 
was done, and to identify and confirm the 
repetition of three nucleotides (CGG) were 
analyzed by Southern blot. Genomic DNA 
digested by the restriction enzyme HindIII 
and methylation-sensitive restriction 
enzymes EclXI . 
DNA that samples were digested and size-
separated by electrophoresis on a % 0.8 
agarose gel with using a DIG-labled 
molecular marker and transferred to a 
positively charged nylon membrane. The 
stb probe specific for fragments containing 
the CGG repeat was labeled using a non-
radioactive label. After hybridization, the 
membrane was washed and labeled probe 
was detected by exposure to an X-ray film. 
Results  
Among the patients studied, the karyotype 
results showed that 5 patients (6%) had 
FXS. Parental consanguinity was found in 
4 patients (4.4 %), and family history of 
MR was found in 21 patients (23.3 %) also 
56 families (62 %) had poor economic 
condition. Of the parameters evaluated in 
the study, only the history of retardation 
was significantly associated with FXS 
(P<0.5). 
Discussion  
The study was aimed to determine the 
linkage between FXS and MR in some of 
the patients with MR of unknown origin. 
According to the results of the study which 
was done on 90 cases with MR, 6% of them 
had FXS. Past studies on the prevalence of 
FXS, based on cytogenetic diagnosis has 
been made, 0.4-0.8 of the 1000 for men and 
0.2-0.6 of 1000 for women, was reported. 
Studies based on molecular methods, the 
frequency of FXS in European countries, 
the US and Australia have shown that is 0.6 
per thousand (19). According to studies 
performed in Turkey (which has a similar 
race to Azerbaijan) 14 of 120 MR case had 
FXS; However its frequency in Turkey is 
11.7% (20). Another study performed in 
Antalya province of Turkey, showed that 17 
of 132 patients had FXS which its 
frequency is 12.87% (21). Jenkins (22) 
reported the frequency of this syndrome 
6.3% among MR cases and Butler reported 
6.4% as the frequency (23-24).In selected 
populations of mentally retarded patients, 
an overall prevalence rate of 4.8% of fragile 
X was reported by Proops et al (19). 
Carpenter et al; studied 36 patients with a 
family history of MR and found 13.9% to 
be fragile X-positive cases. Iqbal et al; 
studied 81 patients with a family history of 
MR; among these, 12 patients (14.8%) were 
found to be fragile X-positive, which is 
similar to the report by Carpenter et al 
(25).Foster reported only 3.6% as the 
frequency in a similar Study which was 
done on 200 MR case with positive familial 
history of the disease [19]. In this study, 3 
of 4 cases of FXS patients had familial 
history of MR. In studies performed in 
various countries, there are some specific 
phenotypes defined for patients with FXS, 
which are the primary criteria to diagnose 
the patient. There is no cure for FXS until 
now, although appropriate decisions and 
drugs can improve the ability of 
individuals. The increased understanding of 
the molecular mechanisms of disease in 
FXS has led to the development of therapies 
targeting the affected pathways. 
Management of FXS may include speech 
therapy, behavioral therapy, sensory 
integration occupational therapy, special 
education, or individualized educational 
plans, and, when necessary, treatment of 
physical abnormalities. Persons with FXS 
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genetic counseling to assess the likelihood 
of having children who are affected, and 
how severe any impairments may be in 
affected descendants.
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